vs

Side-by-side financial comparison of AXCELIS TECHNOLOGIES INC (ACLS) and Ecovyst Inc. (ECVT). Click either name above to swap in a different company.

AXCELIS TECHNOLOGIES INC is the larger business by last-quarter revenue ($238.3M vs $199.4M, roughly 1.2× Ecovyst Inc.). On growth, Ecovyst Inc. posted the faster year-over-year revenue change (34.0% vs -5.6%). Ecovyst Inc. produced more free cash flow last quarter ($22.9M vs $-8.9M). Over the past eight quarters, Ecovyst Inc.'s revenue compounded faster (18.7% CAGR vs -2.8%).

Axcelis Technologies, Inc. is an American company engaging in the design, manufacture, and servicing of capital equipment for the semiconductor manufacturing industry worldwide. It produces ion implantation systems, including high and medium current implanters, and high energy implanters, and curing systems used in the fabrication of semiconductor chips. The company was incorporated in 1995 and is headquartered in Beverly, Massachusetts, United States.

Ecovyst Inc. is a global sustainable specialty materials provider that develops and manufactures high-performance catalysts and functional additives. Its offerings serve key segments including industrial manufacturing, consumer goods, and environmental protection, helping clients improve operational efficiency and lower carbon emissions across North America, Europe, and Asia-Pacific markets.

ACLS vs ECVT — Head-to-Head

Bigger by revenue
ACLS
ACLS
1.2× larger
ACLS
$238.3M
$199.4M
ECVT
Growing faster (revenue YoY)
ECVT
ECVT
+39.5% gap
ECVT
34.0%
-5.6%
ACLS
More free cash flow
ECVT
ECVT
$31.8M more FCF
ECVT
$22.9M
$-8.9M
ACLS
Faster 2-yr revenue CAGR
ECVT
ECVT
Annualised
ECVT
18.7%
-2.8%
ACLS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACLS
ACLS
ECVT
ECVT
Revenue
$238.3M
$199.4M
Net Profit
$34.3M
Gross Margin
47.0%
23.4%
Operating Margin
15.2%
10.9%
Net Margin
14.4%
Revenue YoY
-5.6%
34.0%
Net Profit YoY
-31.3%
EPS (diluted)
$1.11
$0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACLS
ACLS
ECVT
ECVT
Q4 25
$238.3M
$199.4M
Q3 25
$213.6M
$204.9M
Q2 25
$194.5M
$176.1M
Q1 25
$192.6M
$143.1M
Q4 24
$252.4M
$148.9M
Q3 24
$256.6M
$153.9M
Q2 24
$256.5M
$154.0M
Q1 24
$252.4M
$141.6M
Net Profit
ACLS
ACLS
ECVT
ECVT
Q4 25
$34.3M
Q3 25
$26.0M
$-79.3M
Q2 25
$31.4M
$6.0M
Q1 25
$28.6M
$-3.6M
Q4 24
$50.0M
Q3 24
$48.6M
$14.3M
Q2 24
$50.9M
$8.3M
Q1 24
$51.6M
$1.2M
Gross Margin
ACLS
ACLS
ECVT
ECVT
Q4 25
47.0%
23.4%
Q3 25
41.6%
25.4%
Q2 25
44.9%
22.8%
Q1 25
46.1%
13.3%
Q4 24
46.0%
28.9%
Q3 24
42.9%
29.3%
Q2 24
43.8%
27.3%
Q1 24
46.0%
23.5%
Operating Margin
ACLS
ACLS
ECVT
ECVT
Q4 25
15.2%
10.9%
Q3 25
11.7%
13.8%
Q2 25
14.9%
9.0%
Q1 25
15.1%
-0.7%
Q4 24
21.6%
15.1%
Q3 24
18.3%
17.9%
Q2 24
20.6%
14.1%
Q1 24
22.4%
9.5%
Net Margin
ACLS
ACLS
ECVT
ECVT
Q4 25
14.4%
Q3 25
12.2%
-38.7%
Q2 25
16.1%
3.4%
Q1 25
14.8%
-2.5%
Q4 24
19.8%
Q3 24
18.9%
9.3%
Q2 24
19.8%
5.4%
Q1 24
20.4%
0.9%
EPS (diluted)
ACLS
ACLS
ECVT
ECVT
Q4 25
$1.11
$0.06
Q3 25
$0.83
$-0.69
Q2 25
$0.98
$0.05
Q1 25
$0.88
$-0.03
Q4 24
$1.54
$-0.26
Q3 24
$1.49
$0.12
Q2 24
$1.55
$0.07
Q1 24
$1.57
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACLS
ACLS
ECVT
ECVT
Cash + ST InvestmentsLiquidity on hand
$374.3M
$197.2M
Total DebtLower is stronger
$392.6M
Stockholders' EquityBook value
$1.0B
$603.4M
Total Assets
$1.4B
$1.3B
Debt / EquityLower = less leverage
0.65×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACLS
ACLS
ECVT
ECVT
Q4 25
$374.3M
$197.2M
Q3 25
$449.6M
$82.0M
Q2 25
$549.8M
$69.6M
Q1 25
$587.1M
$127.5M
Q4 24
$571.3M
$131.4M
Q3 24
$579.4M
$123.5M
Q2 24
$548.3M
$83.3M
Q1 24
$530.2M
$103.1M
Total Debt
ACLS
ACLS
ECVT
ECVT
Q4 25
$392.6M
Q3 25
$854.8M
Q2 25
$856.6M
Q1 25
$859.0M
Q4 24
$860.8M
Q3 24
$862.7M
Q2 24
$862.4M
Q1 24
$866.2M
Stockholders' Equity
ACLS
ACLS
ECVT
ECVT
Q4 25
$1.0B
$603.4M
Q3 25
$1.0B
$607.9M
Q2 25
$1.0B
$692.4M
Q1 25
$1.0B
$698.7M
Q4 24
$1.0B
$700.5M
Q3 24
$975.6M
$729.4M
Q2 24
$934.9M
$717.3M
Q1 24
$901.7M
$711.4M
Total Assets
ACLS
ACLS
ECVT
ECVT
Q4 25
$1.4B
$1.3B
Q3 25
$1.4B
$1.7B
Q2 25
$1.3B
$1.8B
Q1 25
$1.3B
$1.8B
Q4 24
$1.3B
$1.8B
Q3 24
$1.3B
$1.8B
Q2 24
$1.3B
$1.8B
Q1 24
$1.3B
$1.8B
Debt / Equity
ACLS
ACLS
ECVT
ECVT
Q4 25
0.65×
Q3 25
1.41×
Q2 25
1.24×
Q1 25
1.23×
Q4 24
1.23×
Q3 24
1.18×
Q2 24
1.20×
Q1 24
1.22×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACLS
ACLS
ECVT
ECVT
Operating Cash FlowLast quarter
$-6.6M
$41.8M
Free Cash FlowOCF − Capex
$-8.9M
$22.9M
FCF MarginFCF / Revenue
-3.7%
11.5%
Capex IntensityCapex / Revenue
1.0%
9.4%
Cash ConversionOCF / Net Profit
-0.19×
TTM Free Cash FlowTrailing 4 quarters
$107.0M
$69.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACLS
ACLS
ECVT
ECVT
Q4 25
$-6.6M
$41.8M
Q3 25
$45.4M
$55.3M
Q2 25
$39.7M
$33.0M
Q1 25
$39.8M
$10.3M
Q4 24
$12.8M
$43.5M
Q3 24
$45.7M
$59.9M
Q2 24
$40.1M
$10.0M
Q1 24
$42.2M
$36.5M
Free Cash Flow
ACLS
ACLS
ECVT
ECVT
Q4 25
$-8.9M
$22.9M
Q3 25
$43.3M
$53.2M
Q2 25
$37.7M
$7.8M
Q1 25
$34.8M
$-14.0M
Q4 24
$8.1M
$30.9M
Q3 24
$41.8M
$53.6M
Q2 24
$38.1M
$-9.3M
Q1 24
$40.6M
$19.1M
FCF Margin
ACLS
ACLS
ECVT
ECVT
Q4 25
-3.7%
11.5%
Q3 25
20.3%
26.0%
Q2 25
19.4%
4.4%
Q1 25
18.1%
-9.8%
Q4 24
3.2%
20.7%
Q3 24
16.3%
34.9%
Q2 24
14.8%
-6.1%
Q1 24
16.1%
13.5%
Capex Intensity
ACLS
ACLS
ECVT
ECVT
Q4 25
1.0%
9.4%
Q3 25
0.9%
1.0%
Q2 25
1.0%
14.4%
Q1 25
2.6%
16.9%
Q4 24
1.8%
8.5%
Q3 24
1.5%
4.1%
Q2 24
0.8%
12.5%
Q1 24
0.6%
12.3%
Cash Conversion
ACLS
ACLS
ECVT
ECVT
Q4 25
-0.19×
Q3 25
1.75×
Q2 25
1.27×
5.52×
Q1 25
1.39×
Q4 24
0.26×
Q3 24
0.94×
4.21×
Q2 24
0.79×
1.20×
Q1 24
0.82×
29.90×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACLS
ACLS

Products$224.6M94%
Services$13.7M6%

ECVT
ECVT

Industrial Mining Automotive$101.3M51%
Regeneration And Treatment Services$90.0M45%
Other$8.1M4%

Related Comparisons